Allos Limits RSR13 Brain Metastases NDA To Breast Cancer; User Fee In June
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allos expects its radiation sensitizer RSR13 (efaproxiral) to receive a priority review for the treatment of brain metastases from breast cancer, placing the user fee goal date in June.
You may also be interested in...
Allos Efaproxyn "approvable"
Allos' radiation sensitizer Efaproxyn (efaproxiral, RSR-13) is "approvable" May 27 for treatment of brain metastases originating from breast cancer. Approval is contingent upon successful completion of the Phase III ENRICH study. "If the study shows effectiveness in this population (increased survival) using the pre-specified analysis, and the study is otherwise satisfactory, we believe it would, together with the subset result in RT-009, support approval," FDA's letter states. Allos limited the RSR-13 filing to breast cancer after the RT-009 trial showed significance in a subset of patients with breast cancer, but not in the overall population (1Pharmaceutical Approvals Monthly Dec. 1, 2003, p. 6). Allos announced European submission of efaproxiral June 4 for the same indication, under the centralized procedure...
Allos gets NDA rolling for efaproxiral
Allos will complete rolling NDA for its radiation sensitizer efaproxiral (RSR13) by year-end. The final component includes clinical information supporting use of efaproxiral as an adjunct to radiation therapy for the treatment of brain metastases from breast cancer. Allos initiated the submission in August with non-clinical information, and submitted CMC data in September
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011